Treatment with immune checkpoint inhibitors (ICIs) targeting programmed death 1 receptor (PD-1)/programmed death ligand 1 (PD-L1) is a revolutionary development in oncology and has been approved for advanced or metastatic NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic alterations [2,3,4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.